Loading…
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya
Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV–HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV‐infected adults before and for 18 months after starting highly active antiretrovi...
Saved in:
| Published in: | Journal of viral hepatitis 2011-10, Vol.18 (10), p.e447-e452 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4406-5ebbe7e771bb553d8b13896aaea7ab75d8c79c505680ddf34762304dfa6811493 |
|---|---|
| cites | |
| container_end_page | e452 |
| container_issue | 10 |
| container_start_page | e447 |
| container_title | Journal of viral hepatitis |
| container_volume | 18 |
| creator | Kim, H. N. Scott, J. Cent, A. Cook, L. Morrow, R. A. Richardson, B. Tapia, K. Jerome, K. R. Lule, G. John-Stewart, G. Chung, M. H. |
| description | Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV–HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV‐infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty‐seven (6.9%) were HBsAg positive and anti‐HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤10 000 IU/mL. Sustained HBV suppression to |
| doi_str_mv | 10.1111/j.1365-2893.2011.01466.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1328507014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1328507014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4406-5ebbe7e771bb553d8b13896aaea7ab75d8c79c505680ddf34762304dfa6811493</originalsourceid><addsrcrecordid>eNpFUU1P2zAYtibQYLC_gHzkQDJ_xHZy2AHQRimITWjrjpYTv2UuiVvilLWX_XZsWoovfl8_H7KeByFMSU7j-TLLKZciY2XFc0YozQktpMxXH9DhDthLs2AZEaQ4QJ9CmBFCORP0IzpgtKIFkewQ_R9dTHBrOve8tM4D7iG4MBjfADbd3D_gv7AwgxtcwBfYeItH1xPczJ2fQjOAxQkEPwQcRf3gouDd7Cw9bn2T1MOz680irc7jG_Brc4z2p6YN8Hl7H6Hf37_9uhxltz-uri_Pb7OmiP_MBNQ1KFCK1rUQ3JY15WUljQGjTK2ELRtVNYIIWRJrp7xQknFS2KmRJaVFxY_Q6cZ30c-flhAG3bnQQNsaD_Nl0DGYUhAVY4zUky11WXdg9aJ3nenX-i2zSPi6IfxzLax3OCU6daNnOlWgUwU6daNfu9ErPZ6M0hT12UYfg4bVTm_6Ry0VV0L_ubvSPxUbs-pe6DF_AZSdkiY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1328507014</pqid></control><display><type>article</type><title>HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Kim, H. N. ; Scott, J. ; Cent, A. ; Cook, L. ; Morrow, R. A. ; Richardson, B. ; Tapia, K. ; Jerome, K. R. ; Lule, G. ; John-Stewart, G. ; Chung, M. H.</creator><creatorcontrib>Kim, H. N. ; Scott, J. ; Cent, A. ; Cook, L. ; Morrow, R. A. ; Richardson, B. ; Tapia, K. ; Jerome, K. R. ; Lule, G. ; John-Stewart, G. ; Chung, M. H.</creatorcontrib><description>Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV–HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV‐infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty‐seven (6.9%) were HBsAg positive and anti‐HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤10 000 IU/mL. Sustained HBV suppression to <100 IU/mL occurred in 89% of 19 evaluable patients. Resistance occurred in only two subjects, both with high baseline HBV DNA levels. Lamivudine resistance can emerge in the setting of incomplete HBV suppression but was infrequently observed among HIV–HBV coinfected patients with low baseline HBV DNA levels.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/j.1365-2893.2011.01466.x</identifier><identifier>PMID: 21914062</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Anti-HIV Agents - administration & dosage ; Antiretroviral Therapy, Highly Active - methods ; DNA, Viral - blood ; Drug Resistance, Viral ; Female ; Hepatitis B - complications ; Hepatitis B - drug therapy ; Hepatitis B - virology ; Hepatitis B Antibodies - blood ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus ; Hepatitis B virus - drug effects ; Hepatitis B virus - isolation & purification ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV-1 ; Human immunodeficiency virus ; Humans ; Kenya ; Lamivudine - administration & dosage ; lamivudine resistance ; Male ; Nevirapine - administration & dosage ; Stavudine - administration & dosage ; Treatment Outcome ; Viral Load</subject><ispartof>Journal of viral hepatitis, 2011-10, Vol.18 (10), p.e447-e452</ispartof><rights>2011 Blackwell Publishing Ltd</rights><rights>2011 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4406-5ebbe7e771bb553d8b13896aaea7ab75d8c79c505680ddf34762304dfa6811493</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21914062$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, H. N.</creatorcontrib><creatorcontrib>Scott, J.</creatorcontrib><creatorcontrib>Cent, A.</creatorcontrib><creatorcontrib>Cook, L.</creatorcontrib><creatorcontrib>Morrow, R. A.</creatorcontrib><creatorcontrib>Richardson, B.</creatorcontrib><creatorcontrib>Tapia, K.</creatorcontrib><creatorcontrib>Jerome, K. R.</creatorcontrib><creatorcontrib>Lule, G.</creatorcontrib><creatorcontrib>John-Stewart, G.</creatorcontrib><creatorcontrib>Chung, M. H.</creatorcontrib><title>HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV–HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV‐infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty‐seven (6.9%) were HBsAg positive and anti‐HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤10 000 IU/mL. Sustained HBV suppression to <100 IU/mL occurred in 89% of 19 evaluable patients. Resistance occurred in only two subjects, both with high baseline HBV DNA levels. Lamivudine resistance can emerge in the setting of incomplete HBV suppression but was infrequently observed among HIV–HBV coinfected patients with low baseline HBV DNA levels.</description><subject>Adult</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>DNA, Viral - blood</subject><subject>Drug Resistance, Viral</subject><subject>Female</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - isolation & purification</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Kenya</subject><subject>Lamivudine - administration & dosage</subject><subject>lamivudine resistance</subject><subject>Male</subject><subject>Nevirapine - administration & dosage</subject><subject>Stavudine - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNpFUU1P2zAYtibQYLC_gHzkQDJ_xHZy2AHQRimITWjrjpYTv2UuiVvilLWX_XZsWoovfl8_H7KeByFMSU7j-TLLKZciY2XFc0YozQktpMxXH9DhDthLs2AZEaQ4QJ9CmBFCORP0IzpgtKIFkewQ_R9dTHBrOve8tM4D7iG4MBjfADbd3D_gv7AwgxtcwBfYeItH1xPczJ2fQjOAxQkEPwQcRf3gouDd7Cw9bn2T1MOz680irc7jG_Brc4z2p6YN8Hl7H6Hf37_9uhxltz-uri_Pb7OmiP_MBNQ1KFCK1rUQ3JY15WUljQGjTK2ELRtVNYIIWRJrp7xQknFS2KmRJaVFxY_Q6cZ30c-flhAG3bnQQNsaD_Nl0DGYUhAVY4zUky11WXdg9aJ3nenX-i2zSPi6IfxzLax3OCU6daNnOlWgUwU6daNfu9ErPZ6M0hT12UYfg4bVTm_6Ry0VV0L_ubvSPxUbs-pe6DF_AZSdkiY</recordid><startdate>201110</startdate><enddate>201110</enddate><creator>Kim, H. N.</creator><creator>Scott, J.</creator><creator>Cent, A.</creator><creator>Cook, L.</creator><creator>Morrow, R. A.</creator><creator>Richardson, B.</creator><creator>Tapia, K.</creator><creator>Jerome, K. R.</creator><creator>Lule, G.</creator><creator>John-Stewart, G.</creator><creator>Chung, M. H.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201110</creationdate><title>HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya</title><author>Kim, H. N. ; Scott, J. ; Cent, A. ; Cook, L. ; Morrow, R. A. ; Richardson, B. ; Tapia, K. ; Jerome, K. R. ; Lule, G. ; John-Stewart, G. ; Chung, M. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4406-5ebbe7e771bb553d8b13896aaea7ab75d8c79c505680ddf34762304dfa6811493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>DNA, Viral - blood</topic><topic>Drug Resistance, Viral</topic><topic>Female</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - isolation & purification</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Kenya</topic><topic>Lamivudine - administration & dosage</topic><topic>lamivudine resistance</topic><topic>Male</topic><topic>Nevirapine - administration & dosage</topic><topic>Stavudine - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, H. N.</creatorcontrib><creatorcontrib>Scott, J.</creatorcontrib><creatorcontrib>Cent, A.</creatorcontrib><creatorcontrib>Cook, L.</creatorcontrib><creatorcontrib>Morrow, R. A.</creatorcontrib><creatorcontrib>Richardson, B.</creatorcontrib><creatorcontrib>Tapia, K.</creatorcontrib><creatorcontrib>Jerome, K. R.</creatorcontrib><creatorcontrib>Lule, G.</creatorcontrib><creatorcontrib>John-Stewart, G.</creatorcontrib><creatorcontrib>Chung, M. H.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, H. N.</au><au>Scott, J.</au><au>Cent, A.</au><au>Cook, L.</au><au>Morrow, R. A.</au><au>Richardson, B.</au><au>Tapia, K.</au><au>Jerome, K. R.</au><au>Lule, G.</au><au>John-Stewart, G.</au><au>Chung, M. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2011-10</date><risdate>2011</risdate><volume>18</volume><issue>10</issue><spage>e447</spage><epage>e452</epage><pages>e447-e452</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV–HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV‐infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty‐seven (6.9%) were HBsAg positive and anti‐HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤10 000 IU/mL. Sustained HBV suppression to <100 IU/mL occurred in 89% of 19 evaluable patients. Resistance occurred in only two subjects, both with high baseline HBV DNA levels. Lamivudine resistance can emerge in the setting of incomplete HBV suppression but was infrequently observed among HIV–HBV coinfected patients with low baseline HBV DNA levels.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21914062</pmid><doi>10.1111/j.1365-2893.2011.01466.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2011-10, Vol.18 (10), p.e447-e452 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1328507014 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Anti-HIV Agents - administration & dosage Antiretroviral Therapy, Highly Active - methods DNA, Viral - blood Drug Resistance, Viral Female Hepatitis B - complications Hepatitis B - drug therapy Hepatitis B - virology Hepatitis B Antibodies - blood Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B virus - drug effects Hepatitis B virus - isolation & purification HIV Infections - complications HIV Infections - drug therapy HIV-1 Human immunodeficiency virus Humans Kenya Lamivudine - administration & dosage lamivudine resistance Male Nevirapine - administration & dosage Stavudine - administration & dosage Treatment Outcome Viral Load |
| title | HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A17%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HBV%20lamivudine%20resistance%20among%20hepatitis%20B%20and%20HIV%20coinfected%20patients%20starting%20lamivudine,%20stavudine%20and%20nevirapine%20in%20Kenya&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Kim,%20H.%20N.&rft.date=2011-10&rft.volume=18&rft.issue=10&rft.spage=e447&rft.epage=e452&rft.pages=e447-e452&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/j.1365-2893.2011.01466.x&rft_dat=%3Cproquest_pubme%3E1328507014%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4406-5ebbe7e771bb553d8b13896aaea7ab75d8c79c505680ddf34762304dfa6811493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1328507014&rft_id=info:pmid/21914062&rfr_iscdi=true |